Prestige Consumer Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition of a portfolio led by Breathe Right for $1.045 billion is expected to add 20% to revenue, be immediately accretive to margins and EPS, and double international presence, with limited synergies but strong long-term growth prospects and tax benefits.
-
Q3 revenue declined 2.4% year-over-year to $283.4 million, mainly due to Clear Eyes supply constraints, but strong free cash flow and e-commerce growth offset category softness. Fiscal 2026 guidance was narrowed, with EPS expected at $4.54 and free cash flow at $245 million or more.
-
Resilient performance in 2025 was driven by a diversified portfolio, innovation-led brand building, and strong e-commerce growth. Clear Eyes supply recovery is underway, gross margins are set to improve, and capital allocation remains balanced with a focus on M&A and shareholder returns.
-
Q2 revenue and EPS exceeded expectations despite a 3.4% sales decline, driven by timing factors and strong e-commerce growth. Full-year guidance was reiterated, with improved Clear Eyes supply expected in the second half and continued robust free cash flow supporting share repurchases and M&A.
-
Q1 revenue declined 6.6% year-over-year due to eye care supply issues and retail order timing, but gross margin expanded and EPS rose 6%. The company expects supply recovery in the second half, maintains strong free cash flow guidance, and is acquiring Pillar5 to secure long-term eye care supply.
Fiscal Year 2025
-
A diversified consumer healthcare company outlined its three-pillar strategy focused on brand growth, financial strength, and capital allocation, achieving steady organic growth and strong free cash flow. Recent efforts address supply chain challenges in eye care, with ongoing investments in innovation, e-commerce, and M&A to drive long-term value.
-
Management highlighted strong brand connections, portfolio diversity, and a disciplined M&A strategy in a fragmented industry. E-commerce and innovation drive growth, with robust free cash flow supporting acquisitions and shareholder returns. Free cash flow outlook remains $245M+.
-
The business delivered record sales and cash flow in fiscal 2025, with strong brand momentum and a robust innovation pipeline. Consumer shifts toward value channels and ongoing tariff impacts are being managed through cost savings and selective pricing. M&A remains a key growth lever, supported by strong free cash flow and disciplined capital allocation.
-
Record fiscal 2025 results featured revenue over $1.1B, 7% adjusted EPS growth, and strong free cash flow. Fiscal 2026 guidance anticipates continued revenue and margin expansion despite tariff and FX headwinds, with disciplined capital allocation and ongoing innovation supporting growth.
-
Record Q3 sales and EPS were driven by strong international and North American growth, with robust free cash flow and improved leverage. Fiscal 2025 guidance was raised for EPS, while free cash flow and revenue outlooks remain strong.
-
Management highlighted a strong capital structure, targeting $1 billion in free cash flow over four years, and resilient margins in the low to mid-30% range. Cough and cold products are a small part of sales, and inflation impacts are managed through pricing power and innovation.
-
Q2 sales slightly declined year-over-year due to Clear Eyes supply issues, but strong international and Canadian growth offset most declines. Free cash flow and EPS improved, and guidance for fiscal 2025 remains positive with expectations for higher EPS and continued debt reduction.
-
Q1 2025 results exceeded expectations despite a 4.4% revenue decline, with strong international and e-commerce growth offsetting North America softness. Guidance for FY25 is reaffirmed, with continued focus on brand investment, supply chain recovery, and capital allocation.
Fiscal Year 2024
-
The discussion highlighted a focus on brand leadership, innovation, and diversified growth, with e-commerce and international segments expanding. Supply chain and cost management remain priorities, while strong cash flow supports investment, M&A, and share repurchases.
-
The business now has a focused consumer healthcare portfolio with steady 2%-3% organic growth, driven by trusted brands, innovation, and expanding international and e-commerce presence. Supply chain issues are being resolved, and capital allocation is shifting to M&A and buybacks. Omnichannel strategies and industry consolidation offer new growth opportunities.
-
Management outlined a three-part strategy focused on brand investment, disciplined capital allocation, and innovation. Eye care supply chain disruptions are seen as temporary, with brand loyalty expected to limit share loss. International and e-commerce segments are growing, and financial targets remain on track.